⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent marginal zone lymphoma

Every month we try and update this database with for recurrent marginal zone lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00019708
Extranodal Marg...
Nodal Marginal ...
Non-Hodgkin Lym...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
tanespimycin
19 Years - National Cancer Institute (NCI)
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerNCT00723099
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 YearsFred Hutchinson Cancer Center
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationNCT00003056
Leukemia
Lymphoma
Graft Versus Ho...
cyclosporine
cyclosporine an...
18 Years - 55 YearsTakeda
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell CancerNCT00546377
Leukemia
Lymphoma
filgrastim
pegfilgrastim
rituximab
sargramostim
cyclophosphamid...
mitoxantrone hy...
pentostatin
fluorescence in...
gene rearrangem...
polymerase chai...
protein express...
flow cytometry
biopsy
18 Years - 120 YearsMemorial Sloan Kettering Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaNCT03479268
B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell TransplantationNCT00003143
Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Bone Marrow Transplantation in Treating Patients With LymphomaNCT00002829
Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 YearsM.D. Anderson Cancer Center
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaNCT00538187
Adult Non-Hodgk...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
obatoclax mesyl...
bortezomib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Beta Alethine in Treating Patients With Low-Grade LymphomaNCT00007839
Lymphoma
beta alethine
18 Years - National Cancer Institute (NCI)
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00119392
B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaNCT01381692
Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI)
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaNCT00265928
Lymphoma
bortezomib
rituximab
antibody therap...
biological ther...
enzyme inhibito...
monoclonal anti...
18 Years - National Cancer Institute (NCI)
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaNCT00101244
Adult Grade III...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202NCT00896662
Lymphoma
Solid Tumor
immunologic tec...
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesNCT00376519
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
Secondary Myelo...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
Treg cell infus...
umbilical cord ...
total-body irra...
18 Years - 45 YearsMasonic Cancer Center, University of Minnesota
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaNCT00397800
Lymphoma
rituximab
cyclophosphamid...
fludarabine pho...
yttrium Y 90 ib...
50 Years - 75 YearsTechnical University of Munich
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaNCT00005601
Lymphoma
rituximab
cisplatin
cytarabine
dexamethasone
sargramostim
18 Years - Alliance for Clinical Trials in Oncology
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's LymphomaNCT00007852
Lymphoma
rituximab
carmustine
cytarabine
etoposide
melphalan
autologous hema...
19 Years - University of Nebraska
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's LymphomaNCT00006039
Lymphoma
Small Intestine...
pegylated inter...
18 Years - Memorial Sloan Kettering Cancer Center
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04659044
Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's LymphomaNCT00278161
Leukemia
Lymphoma
Pegfilgrastim
Rituximab
Cyclophosphamid...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyNCT00891137
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 YearsCellerant Therapeutics
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's LymphomaNCT00004192
Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 YearsUniversity of Nebraska
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaNCT00007865
Lymphoma
rituximab
carboplatin
etoposide
ifosfamide
19 Years - 120 YearsUniversity of Nebraska
Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's LymphomaNCT00002697
Lymphoma
filgrastim
sargramostim
carboplatin
etoposide
ifosfamide
autologous bone...
bone marrow abl...
peripheral bloo...
radiation thera...
18 Years - 65 YearsMemorial Sloan Kettering Cancer Center
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00244985
Lymphoma
rituximab
pegylated lipos...
18 Years - 120 YearsRoswell Park Cancer Institute
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNCT01812005
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
alisertib
rituximab
laboratory biom...
18 Years - Ohio State University Comprehensive Cancer Center
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell TransplantationNCT00003143
Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00082823
Cancer
ziv-aflibercept
18 Years - 120 YearsRegeneron Pharmaceuticals
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesNCT04205409
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Non-H...
Recurrent Plasm...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Marg...
Refractory Non-...
Refractory Plas...
Recurrent Mantl...
Refractory Mant...
Nivolumab
18 Years - University of Washington
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00002908
Leukemia
Lymphoma
bryostatin 1
vincristine sul...
18 Years - Barbara Ann Karmanos Cancer Institute
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT02992522
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT02992522
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
Rituximab Plus Interleukin-2 in Treating Patients With LymphomaNCT00003356
Lymphoma
aldesleukin
rituximab
18 Years - 75 YearsUniversity of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)NCT00005626
Leukemia
Lymphoma
Irinotecan
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaNCT00017472
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Stage III Margi...
Stage III Small...
Stage IV Margin...
Stage IV Small ...
apolizumab
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaNCT03479268
B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiaNCT00005786
Extranodal Marg...
Nodal Marginal ...
Prolymphocytic ...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Waldenström Mac...
arsenic trioxid...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00040950
Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI)
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00062296
Leukemia
Lymphoma
rituximab
epirubicin hydr...
18 Years - Fox Chase Cancer Center
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaNCT00691652
Lymphoma
rituximab
clofarabine
DNA methylation...
gene expression...
microarray anal...
polymerase chai...
high performanc...
laboratory biom...
18 Years - 89 YearsOHSU Knight Cancer Institute
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaNCT01045928
Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaNCT00110071
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerNCT00010192
B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaNCT00002779
Lymphoma
fludarabine pho...
octreotide acet...
18 Years - Alliance for Clinical Trials in Oncology
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaNCT02281279
B-cell Adult Ac...
Extranodal Marg...
Intraocular Lym...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Hair...
Small Intestine...
Splenic Margina...
Testicular Lymp...
Waldenström Mac...
rituximab
lenalidomide
romidepsin
laboratory biom...
18 Years - Mayo Clinic
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaNCT04635683
Recurrent B-Cel...
Recurrent Extra...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Extr...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Refractory Wald...
Lenalidomide
Ublituximab
Umbralisib
18 Years - Ohio State University Comprehensive Cancer Center
PS-341 in Treating Patients With Advanced CancerNCT00006362
Leukemia
Lymphoma
Multiple Myelom...
Precancerous Co...
Unspecified Adu...
bortezomib
18 Years - Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyNCT00003341
Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or LymphomaNCT00006252
Leukemia
Lymphoma
fludarabine pho...
Cyclophosphamid...
PBSC
G-CSF
Donor lymphocyt...
- 69 YearsAlliance for Clinical Trials in Oncology
Bone Marrow Transplantation in Treating Patients With LymphomaNCT00002829
Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 YearsM.D. Anderson Cancer Center
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00005592
Lymphoma
90-Y-ibritumoma...
rituximab
indium In 111 i...
18 Years - University of Alabama at Birmingham
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaNCT02049541
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
PI3K inhibitor ...
rituximab
Pharmacodynamic...
Correlative stu...
18 Years - Ohio State University Comprehensive Cancer Center
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00040950
Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaNCT00110071
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00073918
Anaplastic Larg...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
cyclophosphamid...
etoposide
iodine I 131 to...
quality-of-life...
peripheral bloo...
18 Years - 60 YearsFred Hutchinson Cancer Center
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaNCT00551239
Leukemia
Lymphoma
rituximab
fludarabine pho...
pixantrone dima...
18 Years - 120 YearsCTI BioPharma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasNCT02332980
Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or LeukemiaNCT00019838
Leukemia
Lymphoma
7-hydroxystauro...
fludarabine pho...
18 Years - National Cancer Institute (NCI)
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsNCT00082784
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Refractory Plas...
Splenic Margina...
Waldenstrom Mac...
Bortezomib
Alvocidib Hydro...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's LymphomaNCT00004192
Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 YearsUniversity of Nebraska
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's MacroglobulinemiaNCT00004107
Leukemia
Lymphoma
filgrastim
autologous bone...
peripheral bloo...
indium In 111 m...
yttrium Y 90 ep...
18 Years - 80 YearsGarden State Cancer Center at the Center for Molecular Medicine and Immunology
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaNCT00275080
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Secondary Acute...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Untreated Adult...
Untreated Adult...
vorinostat
decitabine
18 Years - National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00012298
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
yttrium Y 90 ib...
indium In 111 i...
oprelvekin
filgrastim
18 Years - National Cancer Institute (NCI)
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaNCT00621452
B-cell Chronic ...
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Waldenström Mac...
therapeutic aut...
cyclophosphamid...
aldesleukin
polymerase chai...
gene rearrangem...
lymph node biop...
genetically eng...
bone marrow asp...
flow cytometry
laboratory biom...
enzyme-linked i...
- Fred Hutchinson Cancer Center
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaNCT02049541
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
PI3K inhibitor ...
rituximab
Pharmacodynamic...
Correlative stu...
18 Years - Ohio State University Comprehensive Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: